Kevin is a Partner at Polaris Partners. He joined Polaris in 2004 and focuses on investments in healthcare. Prior to joining Polaris, Kevin completed his Ph.D. in genetics at Harvard Medical School.
Kevin is a cofounder of Genocea Biosciences (NASDAQ: GNCA) and Sirtris Pharmaceuticals (NASDAQ:SIRT)(GSK), and was the founding CEO of Editas Medicine and Visterra. He currently represents Polaris as a Director of Editas Medicine, InSeal Medical, Genocea Biosciences, Kala Pharmaceuticals, Neuronetics, Inc., Visterra Inc., Taris Biomedical, and Vets First Choice. Additionally, Kevin serves on the Scientific Advisory Board of the Massachusetts Life Sciences Center (MLSC) and on the Board of Directors of the New England Venture Capital Association (NEVCA).
Mass. Life Sciences Center Scientific Advisory Board, Member
New England Venture Capital Association, Board of Directors
B.A. with highest honors, Rutgers College
Ph.D., Harvard Medical School